RA Capital

Imbria Pharmaceuticals develops innovative therapies that target cardiometabolic disorders by leveraging insights from cellular metabolism. The company focuses on creating medicines that aim to improve the lives of patients suffering from these conditions. By translating scientific research into practical treatments, Imbria addresses significant unmet medical needs in the cardiometabolic space. Their research efforts are directed towards understanding the underlying mechanisms of disease, which informs the development of their therapeutic candidates. Through this approach, Imbria Pharmaceuticals contributes to advancing healthcare solutions for individuals affected by cardiometabolic issues.